Based on the Fate Therapeutics Inc stock forecast from 8 analysts, the average analyst target price for Fate Therapeutics Inc is USD 6.30 over the next 12 months. Fate Therapeutics Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Fate Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Fate Therapeutics Inc’s stock price was USD 4.54. Fate Therapeutics Inc’s stock price has changed by -19.50% over the past week, -31.32% over the past month and -27.01% over the last year.
No recent analyst target price found for Fate Therapeutics Inc
No recent average analyst rating found for Fate Therapeutics Inc
Company Overview Fate Therapeutics Inc
N/A
N/A
N/A
N/A
USD
USA
Adjusted Closing Price for Fate Therapeutics Inc (FATE)
Loading...
Unadjusted Closing Price for Fate Therapeutics Inc (FATE)
Loading...
Share Trading Volume for Fate Therapeutics Inc Shares
Loading...
Compare Performance of Fate Therapeutics Inc Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for FATE
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Fate Therapeutics Inc (Sector: Biotechnology )
Frequently Asked Questions About Fate Therapeutics Inc (FATE) Stock
Based on ratings from 8 analysts Fate Therapeutics Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, 1 sell and 7 hold ratings.
Unfortunately we do not have enough data on FATE's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for FATE is USD 6.30 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on FATE's stock to indicate if its overvalued.
The last closing price of FATE's stock was USD 4.54.
The most recent market capitalization for FATE is USD 0.75B.
Based on targets from 8 analysts, the average taret price for FATE is projected at USD 6.30 over the next 12 months.
This means that FATE's stock price may go up by +38.77% over the next 12 months.
We can't find any ETFs which contains Fate Therapeutics Inc's stock.
Sorry, we do not have any data on the number of employees for Fate Therapeutics Inc.
Sorry we do not have any infomation available on Fate Therapeutics Inc's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for FATE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
